Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Inclusion Criteria: * Patients must have histological or cytological confirmed malignancy in the following disease groups: melanoma, non-small cell lung carcinoma, renal cell carcinoma or squamous cell head and neck carcinoma, for which no standard effective or curative options are available * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Documented evidence of disease progression during 6 month period prior to the time of enrollment * Prior therapy requirements: * At least \>= 1 prior completed chemotherapy regimen including chemotherapy, biologic, immunologic or targeted therapy * At least 4 weeks from last dose of prior chemotherapy with resolution of the acute toxic effects of the therapy * At least 2 weeks from completion of prior radiation therapy * At least 4 weeks from last dose of prior investigational therapy * Not receiving any current anti-cancer therapy * At least 4 weeks from last dose of interferon or IL-2 therapy * At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-programmed cell death 1 (PD1) * At least 4 weeks from last dose of prior other biologic agents * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Karnofsky \> 70%) * Absolute lymphocytes \> 500/mcL * Absolute neutrophil count \> 1,000/mcL * Platelets \> 100,000/mcL * Total bilirubin within normal institutional limits * …